Global Fam-Trastuzumab Deruxtecan Market Strategic Research Report

Scope of the Report

The global Fam-Trastuzumab Deruxtecan market size is predicted to grow from US$ 4,278 million in 2025 to US$ 17,575 million in 2032; it is expected to grow at a CAGR of 18.5% from 2026 to 2032.

Fam-Trastuzumab Deruxtecan (T-DXd) is a new-generation human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC). It is covalently composed of a humanized anti-HER2 monoclonal antibody, a cleavable tetrapeptide linker, and DXd, a topoisomerase I inhibitor, with a high drug-to-antibody ratio of 8:1. The drug specifically binds to the HER2 receptor on the surface of tumor cells, and releases highly potent cytotoxic payloads after internalization into cells. It exerts a strong anti-tumor effect by inhibiting DNA replication and inducing apoptosis, and also exhibits a bystander killing effect, showing significant activity against HER2-low expressing tumors. Clinically, it is mainly used for the treatment of solid tumors such as HER2-positive breast cancer, gastric cancer, esophageal cancer and non-small cell lung cancer. With excellent efficacy and favorable safety, it has become a landmark anti-tumor drug with the broadest indications and outstanding clinical value among global ADCs.In 2025, global Fam-Trastuzumab Deruxtecan production reached approximately 4,373,000 vials.

As a benchmark product in the global ADC drug sector, fam-trastuzumab deruxtecan has become a core therapeutic option for HER2-positive solid tumors due to its superior clinical efficacy, broad indication layout, and leading technological advantages. Its market position is supported by multiple barriers: in terms of efficacy, the drug is not only the gold standard for second-line treatment of HER2-positive breast cancer but also pioneeringly covers HER2-low expressing populations, significantly expanding its applicable scope. In indication expansion, it has been approved for multiple cancers including breast cancer, gastric cancer, and non-small cell lung cancer, with ongoing research in early-stage treatment and combination therapy. Commercially, it has achieved rapid global penetration, and its accessibility in China has greatly improved after inclusion in medical insurance, making it a core growth engine.

In the current competitive landscape, fam-trastuzumab deruxtecan maintains an absolutely dominant position. Although facing competition from domestic agents such as disitamab vedotin and ado-trastuzumab emtansine in China, it retains a stable market share owing to its advantages in efficacy and breadth of indications. In the future, with the approval of new indications, deeper deployment in early treatment, and wider medical insurance coverage worldwide, its market potential will be further unlocked. Meanwhile, the rapid rise of domestic ADC drugs will intensify competition, forcing it to consolidate its leading position through technological upgrading, price optimization, and differentiated strategies.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Fam-Trastuzumab Deruxtecan market?

What factors are driving Fam-Trastuzumab Deruxtecan market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Fam-Trastuzumab Deruxtecan market opportunities vary by end market size?

How does Fam-Trastuzumab Deruxtecan break out by Type, by Application?

This report presents a comprehensive overview of the global Fam-Trastuzumab Deruxtecan market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 5.4 mg/kg
• 6.4 mg/kg

Segment by Antibody Type

• Monoclonal Antibody
• Polyclonal Antibody

Segment by Dosage Form

• Lyophilized Powder For Injection
• Concentrate For Intravenous Infusion

Segment by Production Technology

• Innovator
• Generic

Segment by Application

• HER2-Positive Breast Cancer
• HER2-Positive Gastric and Gastroesophageal Junction Cancer
• HER2-Mutant Non-Small Cell Lung Cancer
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Fam-Trastuzumab Deruxtecan market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in HER2-Positive Breast Cancer, HER2-Positive Gastric and Gastroesophageal Junction Cancer, HER2-Mutant Non-Small Cell Lung Cancer evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact